'Unwavering' support helps hospices avoid cuts

Myton Hospices' CEO Ruth Freeman said strong local fundraising has allowed the Warwickshire hospice group to avoid service cuts in 2025 despite rising demand and costs; the three-hospice group’s annual funding need rose from £8.0m in 2015 to £15.3m in 2025. Of the £15.3m needed in 2025, £12.7m was raised through the group's own efforts while roughly 17% came from the NHS; the group has supported nearly 13,000 people over the past decade (about 2,000 in 2025) and plans to add 11 inpatient beds to increase capacity to 36.

Analysis

Winners & losers: Local hospices and private providers gain short-term relief from community fundraising but remain financially constrained: charity funding covered ~83% of Myton Hospices' £15.3m budget in 2025, highlighting acute dependence on donations. Winners include private healthcare operators and healthcare real-estate landlords (higher demand for inpatient beds and leased clinical space); losers are publicly funded services and small charities if donations fall >10% yoy or if NHS grants tighten further.

Competitive dynamics & supply/demand: Rising demand (c.2,000 patients in 2025 at Myton) versus flat/declining NHS funding (17% support here) tilts pricing power toward private providers and landlords of clinical real estate over the next 12–36 months. Expect constrained inpatient supply — a potential 5–15% increase in utilization rates regionally — which benefits asset-light operators and specialty equipment suppliers.

Risk assessment & catalysts: Tail risks include a recession-driven fall in donations >15% (12–18 months), a charity-tax relief cut or tighter regulation (0–6 months), or a policy U-turn increasing NHS funding >3% yoy (30–90 days) that would reverse private providers’ windfall. Hidden dependency: capital expansion plans (adding 11 beds) hinge on successful fundraising and low-cost debt; rising borrowing costs would delay capacity increases.

Trade implications & contrarian angle: Markets likely underprice UK healthcare REITs and select private operators' credit; consensus misses concentrated regional funding risk and upside to real-estate landlords. A near-term policy/cashflow catalyst is the next UK budget/NHS allocation announcement (monitor within 30–90 days) which can re-rate equities and credit spreads by +/-10–25%.

Key Decisions for Investors

• Establish a 2–3% long equity position in Primary Health Properties plc (LSE: PHP) to capture higher utilization of leased clinical space; 12-month target +15–25%, place a stop-loss at -12% and trim if dividend yield compresses below 5% or share rises 25%.
• Add a 1–2% tactical long in Spire Healthcare (LSE: SPI) (or 1% in HCA Healthcare NYSE: HCA for US exposure) on 6–12 month view; scale in on pullbacks >10%, target total return 12 months +20% if NHS waiting lists worsen by >5% QoQ.
• Deploy a conservative options trade: buy a 6‑month call spread on SPI (buy 10% OTM, sell 25% OTM) sized to 0.5% portfolio risk to play a potential policy-driven re-rating around the UK budget/NHS allocation within 30–90 days.
• Allocate 2–4% to IG/upper‑BBB corporate credit of private healthcare operators (or targeted healthcare bond ETF) when spreads >150bp over gilts; exit if spreads tighten below 100bp or issuer downgrade occurs. Monitor UK budget/NHS funding announcements and quarterly donation trends (threshold: donations fall >10% yoy) as immediate triggers to reduce exposure.